Case Report: Clinicopathological features and outcomes of superficial cervicovaginal myofibroblastoma: analysis of two cases and a review of the literature - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Clinical Insights and Outcomes of Superficial Cervicovaginal Myofibroblastoma: A Report on Two Cases and Literature Review

  • By

  • Xiaoli Cai

  • Yanli Liu

  • Yunfeng Niu

  • Xiaodan Shen

  • Qian Zhang

  • Lei Liang

  • Shuang Liu

  • May 13, 2026

Share

  • 1

    Superficial cervicovaginal myofibroblastoma (SCVM) is a rare benign tumor affecting women aged 20–60 years, often misdiagnosed due to overlapping features with other tumors.

  • 2

    Two cases of SCVM were reported, one presenting with vaginal bleeding and the other found incidentally, both diagnosed through histopathological and immunohistochemical evaluation.

  • 3

    Surgical resection of SCVM is the primary treatment, leading to a favorable prognosis with no recurrence observed during follow-up periods of 6 months to 1 year.

  • 4

    Literature review identified 78 cases of SCVM, highlighting its slow growth, benign behavior, and hormone-related characteristics, particularly sensitivity to estrogen.

  • 5

    Accurate diagnosis of SCVM relies on comprehensive assessment of morphological and immunohistochemical features to differentiate it from other mesenchymal tumors.

Original Source(s)

Case Report: Clinicopathological features and outcomes of superficial cervicovaginal myofibroblastoma: analysis of two cases and a review of the literature

  • by Xiaoli Cai, Yanli Liu, Yunfeng Niu, Xiaodan Shen, Qian Zhang, Lei Liang, Shuang Liu

  • May 13, 2026

Related Content

Survival beyond treatment: patterns and determinants of disease-free survival in cervical cancer at a tertiary care center in India

Cost Analysis and Resource Utilization of Gynecologic Cancer-Related Thoracenteses and Paracenteses

Correction: Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer